Voriconazole as Prophylactic Therapy in Lung Transplant Recipients

Phase 4

Terminated

• Conditions: Infection

• Registration Number: NCT00455364
• Lead Sponsor: University of Chicago

Brief Summary

The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation.

Detailed Description

All participants will receive itraconazole during their inpatient post transplant stay. As an outpatient, ten subjects will be randomized to receive itraconazole 200mg orally once daily for 6 month and ten patients to receive voriconazole 200mg orally twice daily for 6 months . All subjects will be followed in the clinic as per the standard transplant treatment

Study Timeline

• Study Start: 2007-04
• Primary Completion: 2007-04
• Study Completion: 2007-04
• Study First Submitted: 2007-04-02
• Study First Submitted QC: 2007-04-02
• Study First Posted: 2007-04-03
• Status Verified: 2013-02
• Last Update Submitted: 2013-02-05
• Last Update Posted: 2013-02-06

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Bilateral-lung or single-lung transplant recipients between the ages of 18- 65 years old.
• Patients must be able to give informed consent prior to and again after transplantation

Exclusion Criteria

• Lung transplant patients unable to give informed consent.
• Prior adverse reaction to the drug itraconazole or voriconazole

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Subject will be monitored for any fungal infection throughout the duration of the study.

Trial Locations

Locations (1)

The University of Chicago; 🇺🇸 Chicago, Illinois, United States